8 results
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
DPP-4 Inhibitors ... - Pharmacology ... #Inhibitors #Pharmacology ... #Summary #DM2 #diabetes ... #endocrinology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
DPP4 Inhibitors ... This drug class ... #Dosing #Pharmacology ... #Management #Diabetes ... #DM2 #Endocrinology
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... events TZDs DPP ... #comparison #management ... #endocrinology
SGLT2 Inhibitors 
SGLT2 inhibitors are the newest class of anti-diabetic medications, with the first one (Canagliflozin)
SGLT2 Inhibitors ... class of anti-diabetic ... #Pharmacology # ... Medications #DM2 #Diabetes ... #Endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Sulfonylurea, TZD, DPP ... -4 inhibitor, GLP ... #Medications #pharmacology ... #comparison #table ... #endocrinology
Euglycemic Diabetic Ketoacidosis (EuDKA)
SGLT2 Inhibitors
Increasing Indications
Significant Adverse Drug Effects
Definition of EuDKA
 • Metabolic acidosis with pH
(EuDKA) SGLT2 Inhibitors ... Significant Adverse Drug ... Effects Definition ... EuDKA #diagnosis #management ... #endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
to remain stable ... empagliflozin and DPP4 ... #semaglutide #Diabetes ... #Pharmacology # ... Endocrinology
Overview of antifungal agents benefits, weaknesses, and adverse effects in the treatment of Coccidioidomycosis.
Fluconazole - Low
weaknesses, and adverse effects ... • Therapeutic drug ... #valleyfever #management ... antifungals #comparison #table ... #pharmacology